Eupraxia Pharmaceuticals vs MediciNova
EPRX and MNOV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EPRX and MNOV compare
MediciNova scores higher on the StockData Score (7 against 5 for Eupraxia Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EPRX | MNOV |
|---|---|---|
| Size and price | ||
| Market cap | – | $68.7M |
| Share price | $8.15 | $1.40 |
| Change, 1 year | 23.5% | −11.1% |
| Change, 5 years | 254% | −56.5% |
| Beta (5Y) | −0.02 | 0.39 |
| Employees | – | 6 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 73.4× |
| P/B | – | 1.7× |
| FCF yield | – | −14.3% |
| Profitability | ||
| Operating margin | – | −1232% |
| Net margin | – | −1127% |
| FCF margin | – | −1048% |
| Return on equity | −66.8% | −24.8% (better) |
| Return on invested capital | – | −78.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 15.12 (better) | 8.75 |
| Altman Z-score | – | −3.99 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 41.1% | 10.5% |
| Held by insiders | 9.7% | 12.8% |
| Insider net buying, 12 months | – | −$1.7M |
| Short interest, % of float | 11.5% | 0.66% |
Go deeper
- EPRX stock overview
- EPRX income statement
- EPRX valuation and score
- MNOV stock overview
- MNOV income statement
- MNOV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.